Fine chemical

Increasing Investments and Fundings in Cell and Gene Therapy Fuelling the Growth of Cell and Gene Therapy Biomanufacturing, Suggests BIS Research Study

Retrieved on: 
Friday, March 24, 2023
Analytik Jena, GE HealthCare, Gene, Sartorius AG, Merck Group, AAV, DSM-IV codes, Danaher Corporation, Becton, Dickinson and Company headquarters, Incidence, Name, Thermo Fisher Scientific, Investment, General Electric Company, Cancer, Cell, Getinge Group, Growth, Research, Exosome, FDA, Center for Urban and Regional Analysis, PCR, Wuxi, Software, Medical device, Pharmaceutical industry, Vaccine, Antibiotics, Fine chemical

FREMONT, Calif., March 24, 2023 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis. 

Key Points: 
  • FREMONT, Calif., March 24, 2023 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis.
  • According to this study, the global cell and gene therapy biomanufacturing market was valued at $12.31 billion in 2022 and is projected to reach $29.76 billion by 2031.
  • Therefore, the impact of the aforementioned factors is expected to drive the global cell and gene therapy biomanufacturing market in the near future."
  • The software solutions segment consists of all the software utilized from manufacturing to logistics in cell and gene therapy biomanufacturing.

Global Bioengineered Protein Drugs Market to Reach $521.3 Billion by 2027: Increasing Prevalence of Chronic Diseases Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, March 24, 2023
Health, Pharmaceutical, Vaccine, Therapy, Administration, COVID-19, Ageing, Cancer, Infection, Solubility, Incidence, Protein, Conditional sentence, Dietary supplement, Pharmaceutical industry, Fine chemical

The global bioengineered protein drugs market was estimated to have been worth $327.6 billion in 2021.

Key Points: 
  • The global bioengineered protein drugs market was estimated to have been worth $327.6 billion in 2021.
  • Between 2022 and 2027, the bioengineered protein drugs market is predicted to grow at a compound annual growth rate (CAGR) of 8%, leading to a market value of $521.3 billion in 2027.
  • An aging population with a myriad of chronic diseases, the need for more effective and targeted therapeutics, and continuous innovation in bioengineered protein drugs are driving the bioengineered protein drugs market.
  • Over the past three decades, bioengineered protein drugs have revolutionized the treatment of infectious diseases, cancer, and chronic immunological diseases.

NMG Provides Operational Update and Files 2022 Financial Reports: Progress in Developing what is Planned to Be North America’s Largest Integrated Source of Natural Graphite Materials for the Energy Transition

Retrieved on: 
Friday, March 24, 2023
Automotive, Mining, Minerals, Alternative Energy, Energy, Alternative Vehicles, Fuels, Natural Resources, Benchmark, Carbon, Mineral, EV, Palm oil, Metal, Benchmark Mineral Intelligence, Caterpillar Inc., NMG, GHG, Multimedia, Attention, Research, Jardins du Nouveau Monde, OSHA, Plant, Biodiversity, PEA, Verified Carbon Standard, Climate change, Investment, Annual report, Rimba Raya Biodiversity Reserve, Engineering, VCS, CO2, CDP, First Nations, Growth, NOU, ESG, Panasonic, NYSE, Economics, Lithium, Renewable energy, Fine chemical, Forestry, Borean languages, Matawinie Regional County Municipality

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Arne H Frandsen, Chair of NMG, declared: “North America and Europe are accelerating the development of their cleantech production capacity.
  • The push towards energy resilience and ESG compliance places NMG’s mining and advanced manufacturing operations in a privileged position.
  • Local, sizeable, carbon-neutral, traceable, ethical, scalable; NMG checks all boxes to become a supplier of choice to leading EV/battery manufacturers.
  • While much has changed in the last decade, there is still a lag in acknowledging minerals and advanced materials as the cornerstones of the energy transition.

OKYO Pharma Announces PDMR Dealing

Retrieved on: 
Friday, March 24, 2023
LSE, Telecanthus, Executive, ADS, Cryptocurrency, Fine chemical

LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED“) to address the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 10,000 of the Company's ADSs on NASDAQ at a price of US$1.40 per ADS (which would be equivalent to the purchase of 650,000 ordinary shares of no par value ("Ordinary Shares") at a price of £0.0175 each).

Key Points: 
  • LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company“), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (“DED“) to address the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 10,000 of the Company's ADSs on NASDAQ at a price of US$1.40 per ADS (which would be equivalent to the purchase of 650,000 ordinary shares of no par value ("Ordinary Shares") at a price of £0.0175 each).

KULR Reports Record Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 23, 2023
Lithium, Database, CES, Advertising, JSC, Lockheed Martin, EV, PPR, SG, Education, Marketing, Safety, ISC, JPL (Integrated Communications, Inc.), Intelligence, Lockheed, Recycling, Satellite, KULR, NASA, Customer, Administration, SAN, Algorithm, CFO, Growth, Gamma, Transport, NYSE, Automation, Video game, Renewable energy, Cryptocurrency, Electric battery, Communications satellite, Pharmaceutical industry, Fine chemical, Artemis

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today announced its financial results for the fourth quarter and full-year 2022.

Key Points: 
  • SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the "Company" or "KULR"), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, today announced its financial results for the fourth quarter and full-year 2022.
  • R&D expenses: R&D expenses in the fourth quarter of 2022 increased to $1,187,000 from $705,000 in the same period last year.
  • Operating Loss: Loss from operations was $3,987,000 for the fourth quarter of 2022, compared to $4,013,000 from the same period last year.
  • Higher SG&A costs offset higher sales while the gross margin increased from 70% in the fourth quarter of 2021 to 92% in the comparable 2022 quarter.

Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates

Retrieved on: 
Thursday, March 23, 2023
ACT, Insurance, HGF, Enzyme inhibitor, Society, Doctor of Philosophy, Athira Pharma, G&A, Open-label trial, St. Kevin's Church, Camden Row, Dublin, Neurotherapeutics, Dementia, Journal, District court, Investment, Administration, Neuropathic pain, Annual general meeting, MET, Lewy body, Growth, Research and development, R, ALS, IND, Douglas v. U.S. District Court ex rel Talk America, Conference, Publishing, Hepatocyte growth factor, Fine chemical, Pharmaceutical industry, Management, Cryptocurrency

BOTHELL, Wash., March 23, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2022, and reviewed recent pipeline and business updates.

Key Points: 
  • BOTHELL, Wash., March 23, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2022, and reviewed recent pipeline and business updates.
  • We are targeting to complete enrollment of the LIFT-AD trial in mid-2023 and to have topline data in early 2024.
  • Fosgonimeton (ATH-1017) - Small molecule designed to enhance the activity of the HGF/MET system with the potential to protect and repair neuronal networks.
  • As of year-end 2022, greater than 85% of participants who have completed either study have elected to enroll in the OLEX trial.

Spruce Power Reports Fourth Quarter and Full Year 2022 Results

Retrieved on: 
Thursday, March 23, 2023
Environment, Residential Building & Real Estate, Alternative Energy, Green Technology, Energy, Construction & Property, Letter, Loss, Event, General Administration of Customs, Telephone, Spruce, Kilowatt-hour, EBITDA, Acquisition, Drivetrain, Conference, NYSE, Common, Cryptocurrency, Fine chemical, Retail, Video game, Pharmaceutical industry

Our investors can read more about our vision in my 2023 CEO’s Letter to Shareholders.” ( link here )

Key Points: 
  • Our investors can read more about our vision in my 2023 CEO’s Letter to Shareholders.” ( link here )
    “Financial results for the fourth quarter of 2022 reflect the first full quarter of contribution from Spruce Power following the acquisition on September 9, 2022,” said Don Klein, Chief Financial Officer of Spruce Power.
  • Selling, general & administrative expenses were $28.6 million for the fourth quarter of 2022, compared to $27.0 million for the third quarter of 2022.
  • Adjusted EBITDA totaled $3.5 million for the fourth quarter of 2022, compared to ($8.3) million for the third quarter of 2022.
  • The Spruce Power management team will host a conference call to discuss its fourth quarter 2022 financial results today at 2:30 p.m. Mountain Time.